Vertex Pharmaceuticals (NQ: VRTX )

494.61 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 565
Open 494.61
Bid (Size) 475.06 (1)
Ask (Size) 496.58 (1)
Prev. Close 494.61
Today's Range 494.61 - 494.61
52wk Range 341.93 - 519.88
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Regulators are reviewing what could become a multi-billion-dollar drug. 
Via The Motley Fool
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets

Performance

YTD
+20.37%
+20.37%
1 Month
+2.02%
+2.02%
3 Month
+4.91%
+4.91%
6 Month
+13.06%
+13.06%
1 Year
+33.70%
+33.70%

More News

Read More
Five S&P 500 Stocks, All Elite IBD Giants, Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
Via Benzinga
Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts
Via Benzinga
2 Biotech Stocks You Can Buy Hand Over Fist This Month
Via The Motley Fool
Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?
Via Benzinga
5 Top Stocks to Buy in November
Via The Motley Fool
My 2 Favorite Growth Stocks to Buy Hand Over Fist in November
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
Via Investor's Business Daily
Vertex Reports Third Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
Via Talk Markets
Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?
Via Benzinga
Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts?
Via Benzinga
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers
Via The Motley Fool
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'
Via Benzinga
Vertex to Participate in Upcoming November Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
These 10 Stocks Were The Best S&P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
12 High-Growth Stocks That Could Deliver Parabolic Returns
Via The Motley Fool
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The Smartest Growth Stock to Buy With $500 Right Now
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.